Table 1 Comparison of perioperative factors between the S1 completion and incompletion groups in the Ehime study.

From: Novel modified frailty index predicts completion of adjuvant chemotherapy in resectable pancreatic cancer in a dual center study

Characteristics

Complete

(n = 69)

Incomplete

(n = 17)

P value

Sex (male)

29

11

0.11

Age (year)

70 (47–84)

73 (56–85)

0.107

Body mass index (kg/m2)

22.5 (14.0–28.9)

21.6 (16.9–25.8)

0.288

NAC

19

5

 > 0.999

Surgical procedure

  

0.385

 Distal pancreatectomy

27

4

 

 Pancreatoduodenectomy

39

13

 

 Total pancreatectomy

3

0

 

 Major postoperative complications

20

3

0.542

Pathological Stage

  

0.799

 I

14

4

 

 II

54

13

 

 III

1

0

 

DM

29

7

 > 0.999

HT

31

12

0.102

CHF

5

7

0.002

COPD

0

2

0.037

Independent status

0

3

0.006

Data at the onset of AC

   

 Alb (mg/dL)

3.8 (2.9–4.4)

3.2 (2.7–4.5)

 < 0.001

 CRP (mg/dL)

0.08 (0.01–2.15)

0.62 (0.03–6.02)

 < 0.001

 CEA (ng/mL)

1.8 (0.6–12)

2.6 (0.6–10)

0.234

 CA19-9 (U/mL)

11 (2–1532)

25 (2–350)

0.004

mFI-5

16 (23.2%)

7 (41.2%)

0.219

mFI-6

24 (34.8%)

13 (76.5%)

0.003

  1. NAC neoadjuvant chemotherapy, POCs postoperative complications, DM diabetes mellitus, HT hypertension, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, AC adjuvant chemotherapy, Alb Albumin, CRP C-reactive protein, CEA Carcinoembryonic antigen, CA19-9 carbohydrate antigen19-9, mFI modified frailty index.